Amevive First to Enter Psoriasis MarketCompetitor Products Closing In Quickly

Author：

ISSN： 1176-3469

Source： Pharmaceutical & Diagnostic Innovation, Vol.1, Iss.2, 2003-01, pp. : 23-26

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Wave of Biotech Drugs Set to Flood the Psoriasis Market: Amevive Rides the Crest

Pharmaceutical Innovation, Vol. 11, Iss. 6, 2002-10 ,pp. : 16-19

Adis International

Access to resources Recommend Favorite

Epigenomics Poised to Enter Cancer Diagnostics Market with DNA Methylation Marker Technology

Pharmaceutical & Diagnostic Innovation, Vol. 2, Iss. 5, 2004-10 ,pp. : 51-55

Adis International

Access to resources Recommend Favorite

Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status

By Kelland L.R.

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 12, 2000-12 ,pp. : 2903-2911

Informa Healthcare

Access to resources Recommend Favorite

Aceclofenac: First report of psoriasis: case report

Reactions Weekly, Vol. 1, Iss. 1123, 2006-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Meloxicam: First report of psoriasis: case report

Reactions Weekly, Vol. 1, Iss. 1123, 2006-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite